# GCC Celiac Disease Treatment Market > GCC Celiac Disease Treatment Market Research Report: Size, Share, Trend Analysis By Treatment Type (Gluten Free Diet, Vitamin and Minerals Supplements, Medical Therapies) and By End Users (Hospitals and Clinics, Research Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 11.04% - **2024:** $ 15.5 Million - **2025:** $ 17.21 Million - **2035:** $ 49.06 Million - **Key Players:** AbbVie Inc (US), Gluten Free Holdings Inc (US), General Mills Inc (US), Kraft Heinz Co (US), Nestle SA (CH), Dr. Schar AG (IT), Cerealto Siro Foods (ES), Boulder Brands Inc (US), Enjoy Life Foods (US) **Report ID:** MRFR/HC/49602-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-celiac-disease-treatment-market-51359 --- ## Market Summary ## **GCC Celiac Disease Treatment Market Overview** As per MRFR analysis, the GCC Celiac Disease Treatment Market Size was estimated at 16.48 (USD Million) in 2023. The GCC Celiac Disease Treatment Market Industry is expected to grow from 18.3(USD Million) in 2024 to 54.9 (USD Million) by 2035. The GCC Celiac Disease Treatment Market CAGR (growth rate) is expected to be around 10.503% during the forecast period (2025 - 2035). **Key GCC Celiac Disease Treatment Market Trends Highlighted** The GCC Celiac Disease Treatment Market is witnessing notable trends driven by several factors. There is a growing awareness of celiac disease among both healthcare professionals and the general public in the GCC region. This is partly due to increased diagnostic capabilities and educational campaigns by health ministries in countries like Saudi Arabia and the UAE, which aim to inform people about gluten intolerance and its health implications. The rising prevalence of celiac disease in the region is another key driver, pushing healthcare systems to focus on better treatment options, such as gluten-free dietary products and medications aimed at managing symptoms.Opportunities in the GCC markets are evolving as more local manufacturers are entering the gluten-free category, prompted by the growing demand for these products. The cost of investment in this market niche is being facilitated by the government on the grounds of public health promotion regarding gluten-free diets, and increased efforts towards improving transparency in the food supply chain. In addition, the active role of some food manufacturers is collaborating with medical specialists for the design of advanced medicine for celiac disease and other related diseases. Recent observation indicates that the distribution of gluten-free products is shifting towards e-commerce in the GCC region. This trend is making gluten-free options more accessible, allowing consumers to purchase necessary foods conveniently. Additionally, there is a rising interest in organic and natural gluten-free products, driven by a general trend towards healthier lifestyles in the region. As these trends continue to evolve, they present significant opportunities for businesses and stakeholders aiming to cater to the growing demand for celiac disease treatments in the GCC. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** **GCC Celiac Disease Treatment Market Drivers** **Rising Awareness and Diagnosis of Celiac Disease** In the GCC region, there has been a significant increase in awareness surrounding celiac disease, which is primarily attributed to public health initiatives and educational campaigns by various health organizations. The World Health Organization has reported that health awareness campaigns are crucial in encouraging diagnostic testing, leading to a 15% increase in diagnosis rates of celiac disease in the Middle East over the past five years. This surge in diagnoses not only contributes to early treatment but also drives the demand for more innovative and effective treatment options within the GCC Celiac Disease Treatment Market Industry.Local health ministries across GCC countries are improving the availability of resources for screening and testing, further solidifying the increasing focus on patient health and management of celiac disease. **Innovative Product Development and Research Advances** The GCC Celiac Disease Treatment Market Industry is being driven by significant advancements in research and development efforts to find new treatments and therapies. Organizations such as the Qatar Biomedical Research Institute have initiated various studies targeting innovative gluten-free products and pharmacological treatments. With ongoing research, the region has seen a 20% increase in gluten-free product introductions between 2019 and 2023.Such innovation enhances treatment options available to consumers with celiac disease and encourages a greater market share as patients look for more viable dietary alternatives that supplement their gluten-free needs. **Increase in Dietary Preferences Among Consumers** Across the GCC region, there has been a noticeable shift in dietary preferences, with more consumers embracing gluten-free diets for health benefits beyond celiac disease. Research indicates that approximately 30% of the population in contemporary GCC society is opting for gluten-free alternatives due to various health trends, which indirectly supports the GCC Celiac Disease Treatment Market through higher demand for gluten-free products and treatments.Renowned organizations such as the Saudi Food and Drug Authority have recognized this trend and have been proactive in regulating gluten-free product standards to cater to the growing market. This creates a robust framework for manufacturers, encouraging the development of gluten-free food products that are widely available to celiac patients and health-conscious consumers. **GCC Celiac Disease Treatment Market Segment Insights** **Celiac Disease Treatment Market Treatment Type Insights** The GCC Celiac Disease Treatment Market encompasses a variety of approaches categorized under Treatment Type, which includes Gluten Free Diet, Vitamin and Minerals Supplements, and Medical Therapies. The significance of the Gluten Free Diet cannot be overstated, as it remains the cornerstone of managing celiac disease. Patients adhere to this diet to alleviate symptoms and prevent long-term complications, reflecting a strong cultural shift towards healthier eating habits within the GCC region. The rise in awareness about gluten intolerance and celiac disease among the population has paved the way for an increasing demand for gluten-free options, with supermarkets and restaurants in places such as the UAE and Saudi Arabia expanding their offerings significantly. Vitamin and Minerals Supplements also play a crucial role, as many individuals with celiac disease experience deficiencies due to malabsorption issues directly linked with the disease. This segment has been witnessing substantial growth, driven by the rising health consciousness across GCC countries. Consumers are increasingly recognizing the need to replenish essential nutrients that may be lacking in their diets, thereby fueling demand for specialized supplements. The growing awareness and diagnosis of celiac disease have contributed to a more significant market focus on these nutritional supports.Additionally, Medical Therapies represent an evolving facet of the GCC Celiac Disease Treatment Market. While dietary management remains primary, advancements in medical therapies, such as enzymatic treatments, are being researched and developed. These therapies aim to improve the quality of life for patients by offering alternatives that could complement dietary restrictions, illustrating an evolving landscape for treatment options outside of conventional dieting. As research progresses, there is potential for these therapies to significantly change how celiac disease is managed in the GCC, providing new avenues for treatment that address the symptoms and complications from this condition. Overall, each Treatment Type segment plays a vital role, contributing to the comprehensive management of celiac disease within the GCC. The increasing prevalence of the disease alongside growing consumer knowledge and interest in treatment options ensures that all segments within the GCC Celiac Disease Treatment Market remain relevant and poised for growth. With the region's commitment to enhancing public health and awareness campaigns, combined with the expansion of available products, the future of celiac disease treatment looks optimistic. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** **Celiac Disease Treatment Market End User Insights** The GCC Celiac Disease Treatment Market demonstrates a diverse segmentation within the End User category, which includes Hospitals and Clinics, Research Centers, and Others. Hospitals and Clinics play a critical role as they are primary institutions providing diagnosis and treatment services, contributing significantly to patient management and care. Their established infrastructure and specialized staff are pivotal in handling patients with celiac disease, ensuring they receive appropriate therapies and dietary guidance. Research Centers, on the other hand, are essential for advancing the understanding of celiac disease through innovative research and clinical trials. They explore new treatment options and methodologies, which may lead to groundbreaking therapies, aligning with the growing emphasis on personalized medicine. The 'Others' category comprises pharmacies, dietary consultants, and online health platforms, contributing to patient education and access to gluten-free products. Collectively, this segmentation reflects the growing focus on comprehensive care and innovative treatment solutions for celiac disease within the GCC region, addressing both immediate healthcare needs and long-term research advancements.As the awareness of celiac disease increases in GCC nations, these segments will likely expand, supporting market growth and improvement in patient outcomes. **GCC Celiac Disease Treatment Market Key Players and Competitive Insights** The GCC Celiac Disease Treatment Market is experiencing significant growth due to an increasing awareness of celiac disease and growing demand for effective treatment options among the population. The competitive landscape is characterized by a variety of pharmaceutical companies and healthcare providers that are engaged in the development and commercialization of therapies aimed at managing this autoimmune disorder. As the market expands, organizations are focusing on innovative treatments, strategic partnerships, and research initiatives to enhance their market position. The region's unique demographic trends, along with changes in dietary patterns and lifestyle, have further fueled the demand for effective therapies, leading to a dynamic, competitive environment. Neon Therapeutics has established a notable presence in the GCC Celiac Disease Treatment Market, primarily focusing on innovative treatment modalities that cater to the specific needs of patients with celiac disease. The company's strength lies in its commitment to research and development, which has led to the advancement of novel therapeutic options aimed at improving patient outcomes. Neon Therapeutics has invested in local partnerships to enhance its reach and accessibility in the GCC region, teaming up with healthcare providers to promote awareness and education about celiac disease management. Their ongoing efforts in clinical trials and patient support programs have positioned them as a key player, bringing forth advancements that positively impact the patient experience in the GCC.Pfizer has a considerable market presence in the GCC Celiac Disease Treatment Market, leveraging its global expertise and wide-ranging product portfolio to address the specific needs of patients suffering from celiac disease. The company’s strengths are highlighted in its comprehensive research and development programs that focus on immunology and gastrointestinal health. Pfizer offers a variety of key products and services that are tailored to enhance patient care in this segment. Moreover, the company has shown its commitment to the GCC through strategic mergers and acquisitions aimed at strengthening its capabilities and expanding its product offerings in the region. Pfizer's well-established distribution network and collaborations with regional healthcare providers further enhance its ability to deliver effective treatments efficiently. Their initiatives focused on local market engagement and patient education have solidified their reputation as a leader in the celiac disease treatment market within the GCC. **Key Companies in the GCC Celiac Disease Treatment Market Include** - Neon Therapeutics - Pfizer - Allergan - Merck - Takeda Pharmaceutical - Biomea Fusion - GlaxoSmithKline - Roche - Eli Lilly - Johnson & Johnson - Celgene - AbbVie - Amgen - Novartis - Sanofi **GCC Celiac Disease Treatment Market Industry Developments** The GCC Celiac Disease Treatment Market has seen notable recent developments as several pharmaceutical companies continue to innovate in therapies for celiac disease. In October 2023, Takeda Pharmaceutical announced advancements in its gluten-free dietary management systems aimed at improving patient quality of life in the GCC region. Additionally, Eli Lilly has focused on expanding its clinical trials related to celiac disease treatments, with updates indicating positive responses in their ongoing research activities as of September 2023. Furthermore, Merck and Pfizer are collaborating on a new initiative to provide educational resources to physicians in the GCC, thereby enhancing awareness and diagnosis of the condition.In terms of market growth, several companies have reported increased market valuations due to heightened awareness and diagnosis rates of celiac disease in the Gulf Cooperation Council countries. For instance, GlaxoSmithKline recorded a significant rise in demand for its gluten-related products in the region during Q3 2023. Notably, no recent mergers or acquisitions have been reported among the specified companies within this market in the GCC, indicating a period of stability as firms focus on research and commercially viable solutions. **GCC Celiac Disease Treatment Market Segmentation Insights** **Celiac Disease Treatment Market Treatment Type****Outlook** - Gluten Free Diet - Vitamin and Minerals Supplements - Medical Therapies **Celiac Disease Treatment Market End User****Outlook** - Hospitals and Clinics - Research Centers - Others ## Market Drivers ### Increased Healthcare Expenditure Rising healthcare expenditure in the GCC region is likely to bolster the celiac disease-treatment market. Governments and private sectors are investing more in healthcare infrastructure, which includes the diagnosis and treatment of chronic conditions like celiac disease. This increase in funding may lead to improved access to healthcare services, including specialized treatments and dietary consultations for patients. As healthcare systems evolve and expand, the celiac disease-treatment market could experience enhanced growth opportunities, as more patients gain access to necessary treatments and support services. This trend indicates a positive outlook for the market as healthcare investments continue to rise. ### Support from Patient Advocacy Groups The role of patient advocacy groups in raising awareness about celiac disease is a vital driver for the celiac disease-treatment market. These organizations are actively engaged in educating the public and healthcare professionals about the condition, promoting early diagnosis and effective management strategies. Their efforts contribute to a more informed patient population, which may lead to increased demand for treatment options. In the GCC, the presence of such advocacy groups is growing, and their initiatives are likely to influence healthcare policies and practices. As awareness spreads, the celiac disease-treatment market may benefit from a larger patient base seeking effective solutions for managing their condition. ### Advancements in Diagnostic Technologies Technological innovations in diagnostic methods are significantly impacting the celiac disease-treatment market. Enhanced testing techniques, such as genetic testing and advanced serological assays, are becoming more accessible in the GCC. These advancements facilitate earlier and more accurate diagnoses, which is essential for effective management of celiac disease. As diagnostic capabilities improve, healthcare providers are likely to identify more cases, leading to an increase in the demand for treatment options. The market may see a surge in the adoption of gluten-free products and therapeutic interventions as a direct result of these advancements, thereby driving growth in the celiac disease-treatment market. ### Growing Demand for Gluten-Free Products The increasing consumer demand for gluten-free products is a significant driver for the celiac disease-treatment market. In the GCC, the gluten-free food sector has experienced substantial growth, with market analysts projecting a compound annual growth rate (CAGR) of around 10% over the next few years. This trend is largely fueled by heightened awareness of celiac disease and gluten sensitivity among the population. As more consumers seek gluten-free options, manufacturers are expanding their product lines to cater to this demand. This expansion not only benefits individuals with celiac disease but also supports the overall growth of the celiac disease-treatment market, as it encourages the development of new and innovative treatment solutions. ### Increasing Prevalence of Celiac Disease The rising incidence of celiac disease in the GCC region is a crucial driver for the celiac disease-treatment market. Recent studies indicate that the prevalence of celiac disease in the GCC has increased, with estimates suggesting that approximately 1 in 100 individuals may be affected. This growing awareness among healthcare professionals and the public is likely to lead to more diagnoses, thereby expanding the patient population requiring treatment. As more individuals are identified, the demand for effective treatment options, including gluten-free diets and medical therapies, is expected to rise. Consequently, this trend may stimulate growth in the celiac disease-treatment market, as healthcare providers seek to address the needs of an expanding patient base. ## Future Outlook The [Celiac Disease Treatment Market](https://www.marketresearchfuture.com/reports/celiac-disease-treatment-market-8474) is projected to grow at 11.04% CAGR from 2025 to 2035, driven by increasing awareness, innovative therapies, and rising prevalence. **New opportunities:** - Development of gluten-free product lines for food service industries. Investment in telehealth platforms for remote patient management. Partnerships with biotech firms for novel therapeutic solutions. By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Treatment Type: Gluten Free Diet (Largest) vs. Vitamin and Minerals Supplements (Fastest-Growing) In the GCC celiac disease-treatment market, the Gluten Free Diet segment holds the largest market share, attracting significant interest from consumers and healthcare providers alike. This treatment approach is perceived as a lifestyle change that effectively minimizes symptoms, placing it as the go-to option for many patients. Meanwhile, Vitamin and Minerals Supplements represent an emerging segment that has been increasingly gaining traction due to growing awareness regarding nutrient deficiencies associated with celiac disease. Growth trends in this market segment are driven by heightened awareness of celiac disease and the need for holistic dietary management. The Gluten Free Diet remains dominant due to its foundational role in celiac disease treatment. However, the fastest growth is witnessed in Vitamin and Minerals Supplements, as advances in nutritional science and increasing recommendations from healthcare providers encourage patients to utilize these products to achieve optimal health outcomes. Gluten Free Diet: Dominant vs. Vitamin and Minerals Supplements: Emerging The Gluten Free Diet is established as the dominant treatment approach for celiac disease, offering a clear path to alleviating symptoms through strict adherence to gluten elimination. This treatment option is deeply ingrained in the lifestyle of many patients, supported by a wide range of gluten-free food products available in the market. In contrast, Vitamin and Minerals Supplements are emerging rapidly, reflecting the growing acknowledgment of the nutritional gaps that may arise from celiac disease. These supplements cater to patients seeking to bolster their diet with essential vitamins and minerals that are often lacking, thereby enhancing overall well-being. The increasing integration of these supplements into treatment regimens demonstrates a holistic shift in how celiac disease is managed. ### By End User: Hospitals and Clinics (Largest) vs. Research Centers (Fastest-Growing) In the GCC celiac disease-treatment market, Hospitals and Clinics account for a significant share, representing the largest segment due to their extensive patient access and resource capabilities. These institutions are primary providers of necessary treatments and diagnostics, reflecting their critical role in the overall healthcare landscape. Research Centers, while holding a smaller share, exhibit rapid growth as they focus on innovative treatment options and advancements in disease understanding, catering to the increasing demand for specialized solutions. Growth trends in this segment are driven by rising awareness about celiac disease and the need for effective treatment options among the population. Hospitals and Clinics benefit from established infrastructure and patient relationships, facilitating a steady flow of treatments. Meanwhile, Research Centers are becoming more prominent as they attract investments for developing new therapies, driving competition and enhancing treatment availability in the market. Hospitals and Clinics: Dominant vs. Research Centers: Emerging Hospitals and Clinics serve as the dominant players in the GCC celiac disease-treatment market, providing comprehensive healthcare services and having the infrastructure to offer reliable treatments. Their ability to connect directly with patients allows for high treatment volumes, making them crucial in the management of celiac disease. Conversely, Research Centers represent the emerging segment, focusing on cutting-edge research and development of new therapies tailored to celiac disease. These centers play a pivotal role in advancing understanding and treatment options, collaborating with healthcare providers to translate laboratory findings into effective patient care solutions. The growth of both segments is vital to meeting the needs of patients and enhancing treatment efficacy. ### Celiac Disease Treatment Market End User Insights Celiac Disease Treatment Market End User Insights The GCC Celiac Disease Treatment Market demonstrates a diverse segmentation within the End User category, which includes Hospitals and Clinics, Research Centers, and Others. Hospitals and Clinics play a critical role as they are primary institutions providing diagnosis and treatment services, contributing significantly to patient management and care. Their established infrastructure and specialized staff are pivotal in handling patients with celiac disease, ensuring they receive appropriate therapies and dietary guidance. Research Centers, on the other hand, are essential for advancing the understanding of celiac disease through innovative research and clinical trials. They explore new treatment options and methodologies, which may lead to groundbreaking therapies, aligning with the growing emphasis on personalized medicine. The 'Others' category comprises pharmacies, dietary consultants, and online health platforms, contributing to patient education and access to gluten-free products. Collectively, this segmentation reflects the growing focus on comprehensive care and innovative treatment solutions for celiac disease within the GCC region, addressing both immediate healthcare needs and long-term research advancements.As the awareness of celiac disease increases in GCC nations, these segments will likely expand, supporting market growth and improvement in patient outcomes. ## Competitive Benchmarking The celiac disease-treatment market is characterized by a dynamic competitive landscape, driven by increasing awareness of gluten-related disorders and a growing demand for gluten-free products. Key players such as AbbVie Inc (US), General Mills Inc (US), and Dr. Schar AG (IT) are strategically positioned to leverage innovation and regional expansion to capture market share. AbbVie Inc (US) focuses on developing advanced therapeutic solutions, while General Mills Inc (US) emphasizes product diversification within the gluten-free segment. Dr. Schar AG (IT) is known for its commitment to high-quality gluten-free products, which enhances its competitive edge in this niche market. Collectively, these strategies contribute to a moderately fragmented market structure, where competition is intensifying as companies seek to differentiate themselves through quality and innovation.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure remains moderately fragmented, with several players vying for consumer attention. This fragmentation allows for niche players to thrive, while larger corporations leverage their resources to establish a more significant presence. The collective influence of these key players shapes the market dynamics, as they adapt to consumer preferences and regulatory changes. In October AbbVie Inc (US) announced a partnership with a leading research institution to develop a novel therapeutic approach for celiac disease. This collaboration aims to enhance the understanding of the disease's underlying mechanisms, potentially leading to groundbreaking treatment options. The strategic importance of this partnership lies in AbbVie's commitment to innovation, which may position the company as a leader in the therapeutic segment of the market. In September General Mills Inc (US) launched a new line of gluten-free snacks aimed at children, responding to the increasing demand for gluten-free options among younger consumers. This strategic move not only diversifies their product portfolio but also targets a growing demographic that is becoming more health-conscious. The introduction of these products reflects General Mills' focus on innovation and market responsiveness, which could enhance brand loyalty and capture a larger market share. In August Dr. Schar AG (IT) expanded its distribution network in the GCC region by partnering with local retailers to increase accessibility to its gluten-free products. This strategic expansion is crucial for enhancing brand visibility and meeting the rising demand for gluten-free options. By strengthening its distribution channels, Dr. Schar AG (IT) is likely to solidify its market position and cater to a broader consumer base. As of November current competitive trends indicate a shift towards digitalization, sustainability, and the integration of AI technologies in product development and marketing strategies. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This evolution suggests that companies that prioritize these aspects will likely gain a competitive advantage in the celiac disease-treatment market. ## Recent News & Developments The GCC [Celiac Disease Treatment Market](https://www.marketresearchfuture.com/reports/celiac-disease-treatment-market-8474) has seen notable recent developments as several pharmaceutical companies continue to innovate in therapies for celiac disease. In October 2023, Takeda Pharmaceutical announced advancements in its gluten-free dietary management systems aimed at improving patient quality of life in the GCC region. Additionally, Eli Lilly has focused on expanding its clinical trials related to celiac disease treatments, with updates indicating positive responses in their ongoing research activities as of September 2023. Furthermore, Merck and Pfizer are collaborating on a new initiative to provide educational resources to physicians in the GCC, thereby enhancing awareness and diagnosis of the condition.In terms of market growth, several companies have reported increased market valuations due to heightened awareness and diagnosis rates of celiac disease in the Gulf Cooperation Council countries. For instance, GlaxoSmithKline recorded a significant rise in demand for its gluten-related products in the region during Q3 2023. Notably, no recent mergers or acquisitions have been reported among the specified companies within this market in the GCC, indicating a period of stability as firms focus on research and commercially viable solutions. ## Report Scope | MARKET SIZE 2024 | 15.5(USD Million) | | --- | --- | | MARKET SIZE 2025 | 17.21(USD Million) | | MARKET SIZE 2035 | 49.06(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.04% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | AbbVie Inc (US), Gluten Free Holdings Inc (US), General Mills Inc (US), Kraft Heinz Co (US), Nestle SA (CH), Dr. Schar AG (IT), Cerealto Siro Foods (ES), Boulder Brands Inc (US), Enjoy Life Foods (US) | | Segments Covered | Treatment Type, End User | | Key Market Opportunities | Emerging gluten-free product innovations cater to increasing consumer demand in the celiac disease-treatment market. | | Key Market Dynamics | Rising demand for gluten-free products drives innovation in celiac disease treatment options across the region. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What was the overall market valuation of the GCC celiac disease-treatment market in 2024?** A: The overall market valuation was $15.5 Million in 2024. **Q: What is the projected market valuation for the GCC celiac disease-treatment market by 2035?** A: The projected valuation for 2035 is $49.06 Million. **Q: What is the expected CAGR for the GCC celiac disease-treatment market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 11.04%. **Q: Which treatment type segment had the highest valuation in 2024?** A: The Gluten Free Diet segment had the highest valuation at $23.5 Million in 2024. **Q: What are the key players in the GCC celiac disease-treatment market?** A: Key players include AbbVie Inc, Gluten Free Holdings Inc, General Mills Inc, Kraft Heinz Co, Nestle SA, Dr. Schar AG, Cerealto Siro Foods, Boulder Brands Inc, and Enjoy Life Foods. **Q: What was the valuation of the Vitamin and Minerals Supplements segment in 2024?** A: The valuation of the Vitamin and Minerals Supplements segment was $4.65 Million in 2024. **Q: Which end user segment is projected to grow significantly by 2035?** A: The Hospitals and Clinics segment is projected to grow significantly, with a valuation of $18.8 Million in 2035. **Q: What was the valuation of the Medical Therapies segment in 2024?** A: The Medical Therapies segment had a valuation of $3.0 Million in 2024. **Q: How does the valuation of Research Centers compare to other end user segments in 2024?** A: The Research Centers segment had a valuation of $4.5 Million, which is lower than Hospitals and Clinics but higher than Others. **Q: What is the projected growth for the Others end user segment by 2035?** A: The Others segment is projected to reach a valuation of $16.8 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-celiac-disease-treatment-market-51359*